Pavilion Health Today
Supporting healthcare professionals to deliver the best patient care

Data on shingles candidate vaccine presented at ID Week conference

bs_subtitle

New data on shingles candidate vaccine Shingrix was presented at the Infectious Disease Week (ID Week) scientific conference in New Orleans, USA, this week. The data on Shingrix, which is being developed by GSK, examined co-administration of it with the flu vaccine, a flexible dosing schedule and the vaccine’s impact on quality of life. Shingles typically presents as a painful, itchy rash that develops on one side of the body as a result of reactivation of latent chickenpox virus (varicella zoster virus or VZV). Data from many countries indicates that more than 90% of adults have been infected with varicella

---------------------------

This content is restricted to members of Pavilion Health Today. If you are an existing user, please log in. New users may register for free below.

Existing Users Log In
   
New User Registration
captcha
*Required field

Comments are closed.

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read more ...

Privacy & Cookies Policy